Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Delighted to have received the Sustainable Growth Award 2020 by Euronext Belgium @euronext_be #euronext2021 #EuronextAwards https://t.co/GGjpTiFGfi
— UCB News (@ucb_news) 21.01.2021 -
Every woman living with a chronic inflammatory disease deserves the ability to be a champion of her condition. For helpful resources on taking an active role in your care & developing a unique game plan click here: https://t.co/WJ8xePOVUF https://t.co
— UCB News (@ucb_news) 18.01.2021 -
As part of UCB’s commitment to improving the lives of people living with severe diseases, we are pleased to announce the launch of Nile AI,Inc., an independent company focused on fostering a better care management experience for people living with #epilep
— UCB News (@ucb_news) 13.01.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
